| http://www.w3.org/ns/prov#value | - Granted, the Merck-Serono deal (written up here in The Pink Sheet DAILY) takes some getting used to, and the company???s back was against the wall ??? the reimbursement agency had already issued negative opinions twice on Erbitux.The industry, however, doesn???t seem to be particularly proactive in taking some other, potentially less drastic, steps US payers say they want, according to the Rxperts
|
